无抽搐电休克治疗应用于精神分裂症患者的临床效果

Clinical effect of non-convulsive electroconvulsive therapy in patients with schizophrenia

目的:探讨精神分裂症患者应用无抽搐电休克治疗的临床效果。方法:选取我院2017年1月~2020年1月收治的86例精神分裂症患者,按照随机数字表法分为观察组和对照组,各43例。对照组口服利培酮片治疗,基于对照组观察组结合无抽搐电休克进行治疗,两组患者均连续治疗7周。比较治疗后两组患者的临床疗效,治疗前后的血清GLU、TC、TG、PRL水平及PANSS评分。结果:治疗后观察组患者的临床总有效率为88.37%,高于对照组的67.44%;与治疗前相比,治疗后两组患者的阴性因子、阳性因子和一般精神病理量表因子评分均降低,且观察组低于对照组(P<0.05);治疗后两组患者血清PRL水平均升高(P<0.05),但组间比较无显著差异(P>0.05);两组患者血清GLU、TC、TG水平治疗前后及治疗后组间比较均无显著差异(P>0.05)。结论:精神分裂症患者应用无抽搐电休克治疗可有效改善其临床精神症状,降低对血糖血脂及PRL水平的影响,疗效确切且整体安全性较高。

Objective:To investigate the clinical effect of non-convulsive electroconvulsive therapy in patients with schizophrenia.Methods:86 patients with schizophrenia were selected from our hospital from January 2017 to January 2020,and were divided into observation group of 43 cases and control group of 43 cases according to the random number table method.The control group was given oral risperidone tablets treatment,based on the control group observation group combined with non-convulsive electric shock treatment.Both the observation group and the control group were treated for 7 consecutive weeks.The clinical efficacy of the two groups,PANSS score,serum GLU,TC,TG,PRL levels were compared before and after treatment.Results:After treatment,the total clinical effective rate of patients in the observation group and the control group were 88.37% and 67.44%,respectively,and the observation group was higher than the control group.Compared with before treatment,the negative factors,positive factors and general psychopathological scale factors of the two groups decreased after treatment,and the observation group was lower than that of the control group(P<0.05).After treatment,the serum PRL levels of the two groups increased(P<0.05),but there was no significant difference between the groups(P>0.05).There were no significant difference in serum GLU,TC,TG levels between two groups before and after treatment(P>0.05).Conclusion:Application of non-convulsive electroconvulsive therapy in patients with schizophrenia can effectively improve their clinical psychiatric symptoms and reduce the impact on blood sugar,blood lipids and PRL levels,definite efficacy and high overall safety.